Anticoagulant bridging: Prosthetic heart valves, labeling changes, and limiting issues of liability

Formulary

Volumn 37, Issue 9, 2002, Pages 473-475

  Groce III, James B ^a   Vanscoy, Gordon J ^a   Gainor, Carl ^a  

^a CAMPBELL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; TINZAPARIN; WARFARIN;

ANTICOAGULATION; BLEEDING; DRUG EFFICACY; DRUG LABELING; DRUG SAFETY; HEART VALVE PROSTHESIS; HUMAN; MEDICAL DECISION MAKING; MEDICAL LIABILITY; PATIENT CODING; PRACTICE GUIDELINE; PREGNANCY; RISK BENEFIT ANALYSIS; SHORT SURVEY;

EID: 0036718237     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (8)

1. Low molecular weight heparins: A guide to their optimum use in pregnancy
2. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves
3. Low molecular weight heparin after mechanical heart valve replacement
4. Temporary discontinuation of oral anticoagulants: Role of low molecular weight heparin
5. Usefulness of low-molecular weight heparins during post-operative period in mitral mechanical valve replacement: Clinical ischaemic and haemorrhagic complications in 110 cases
6. Is low-molecular weight heparin a safe alternative to unfractionated heparin in patients with mechanical heart valves who must interrupt antithrombotic therapy